Effectiveness and safety of adalimumab biosimilar in inflammatory bowel disease: A multicenter study

ConclusionsAdalimumab biosimilar in usual clinical practice is safe and effective in inducing and maintaining remission in Indian patients with IBD. Steroid-free clinical remission was observed in one third of patients with  UC and CD at 1 year of therapy.ᅟᅟ

Source: Indian Journal of Gastroenterology - January 15, 2019 Category: Gastroenterology Source Type: research